Breaking Finance News

H.C. Wainwright reported on Tesaro Inc (NDAQ:TSRO), stepping up its target to $158.00 earlier today

Showing a price of $120.04, Tesaro Inc (NDAQ:TSRO) traded -0.26% lower on the day. The last stock close price is down -12.26% from the 200-day moving average, compared to the S&P 500 Index which has increased 0.03% over the date range. Tesaro Inc has recorded a 50-day average of $122.26 and a two hundred day average of $134.38. Volume of trade was down over the average, with 392,308 shares of TSRO changing hands under the typical 953,365

H.C. Wainwright upped the price target of Tesaro Inc (NDAQ:TSRO) to $158.00 stating a potential upside of 0.32%.

On 8/17/2017, Evercore ISI released a statement on Tesaro Inc (NDAQ:TSRO) upped the target price from $0.00 to $121.00 that suggested an upside of 0.11%.

Performance Chart

Tesaro Inc (NDAQ:TSRO)

With a total market value of $0, Tesaro Inc has with a one year low of $106.64 and a one year high of $192.94 .

A total of 10 brokers have issued a report on the company. 8 brokerages rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the company a hold, zero analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $89.00.

Brief Synopsis About Tesaro Inc (NDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.